Abstracts Archive - Page 422 of 1683 - ATC Abstracts

2020 American Transplant Congress
Donor Derived Parvovirus B19 Infection
W. Peng, J. Lv, J. Wu, J. Chen
Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
*Purpose: At present,donor derived parvovirus B19 infections are rarely reported. Thus, the incidence of donor derived parvovirus B19 infections in solid organ transplant recipients is…
2020 American Transplant Congress
The Clinical Impact of HCV D+/r- Kidney Transplantation
S. Meade¹, M. A. Simpson², E. D. Walshe², M. E. Akoad², F. D. Gordon²
¹Lahey Clinic, Burlington, MA, ²Transplantation, Lahey Clinic, Burlington, MA
*Purpose: Transplantation of hepatitis C (HCV) positive organs into HCV negative recipients raises concerns regarding potential for infections unresponsive to DAAs. In September 2018, we…
2020 American Transplant Congress
Using HCV Infected Organs and the Challenge of Third-Party Payers
R. Daloul, A. Michaels, L. Sobotka, T. Pesavento, K. Washburn
Comprhensive Transplant Center, The Ohio State University, Columbus, OH
*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral…
2020 American Transplant Congress
Experiences and Challenges Faced by Organ Transplant Recipients with Donor-Derived Hepatitis C Virus Infection
K. Prakash¹, C. Ramirez-Sanchez¹, S. I. Ramirez¹, C. Logan¹, N. Law¹, K. Mekeel², V. Pretorius², S. Aslam¹
¹Medicine, University of California San Diego, San Diego, CA, ²Surgery, University of California San Diego, San Diego, CA
*Purpose: Recently, transplantation of organs from viremic donors with hepatitis C virus (HCV-V) has increased. Currently, there is a lack of standardization of consent forms…
2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
C. Edmonds, A. Carver, J. DeClercq, L. Choi, M. Peter, R. Forbes, B. Concepcion, K. Schlendorf, R. Perri
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…
2020 American Transplant Congress
Effect of JC Virus on Polyomavirus Nephropathy in Renal Transplant Recipients
G. Huang, Y. Huang, X. Chen, J. Qiu, J. Li, C. Wang, L. Chen
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
*Purpose: To investigate the effect of JC virus (JCV) on the development and prognosis of BK virus (BKV) infection and polyomavirus nephropathy (PVN) in renal…
2020 American Transplant Congress
Incidence and Risks Factors of Kidney Allograft Loss Due to BK Virus: UNOS Data Set
H. Patel¹, K. Agrawal¹, A. Pawar¹, N. Leeaphorn², F. Cardarelli¹, N. Agrawal¹
¹Transplant Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Transplant Nephrology, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, MO
*Purpose: BK virus infection can lead to graft dysfunction and loss in kidney transplant patients. Incidence and prevalence of BK Viremia (BKV) and BK Virus…
2020 American Transplant Congress
Experience with a BKV-Specific, Neutralizing Monoclonal Antibody (MAU868) for Treatment of Severe BK Virus Nephropathy (BKVN) after Kidney Transplant (FDA EIND #139112)
S. C. Jordan¹, S. J. Kovacs², J. R. Abend³, N. Ammerman¹, M. Toyoda¹, C. C. Nast¹, E. Huang¹, R. Najjar¹, S. Sethi¹, A. Peng¹, K. Lim¹, M. R. Hodges⁴, A. Vo¹
¹Cedars Sinai Medical Ctr, Los Angeles, CA, ²Novartis Institutes for BioMedical Research, East Hanover, NJ, ³Novartis Institutes for BioMedical Research, Emeryville, CA, ⁴Amplyx Pharmaceuticals, San Diego, CA
*Purpose: BK viral reactivation leading to nephropathy and allograft loss in kidney transplant recipients remains a significant challenge. No effective BKV-therapies are currently available. Management…
2020 American Transplant Congress
Hepatitis C Antibody Seroconversion after Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
U. A. Agbim¹, O. Cseprekal², M. Yazawa¹, M. Talwar¹, V. Balaraman¹, A. Bhalla¹, P. S. Podila³, B. Maliakkal¹, S. Nair¹, J. D. Eason¹, M. Z. Molnar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ³Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, TN
*Purpose: We aimed to assess factors associated with hepatitis C virus (HCV) seroconversion among HCV seronegative kidney transplant candidates receiving HCV infected donor kidneys.*Methods: This…
2020 American Transplant Congress
Osmotic Nephropathy from a Non-Sucrose Based IVIG
S. Reddy, L. Kodali
Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: We present a case of acute renal failure and hyperkalemia due to osmotic nephropathy from a non-sucrose based IVIG infusion therapy.*Methods: A 67-year-old man…